SlideShare una empresa de Scribd logo
1 de 46
Sodium intake and mortality Perspectives on the evidence from the U.S. National Health and Nutrition Examination Surveys (NHANES) Hillel W. Cohen, MPH, DrPH Associate Professor of Epidemiology and Population Health Albert Einstein College of Medicine, Bronx NY
The Sodium Hypothesis Higher Sodium (Na) Intake Elevated Blood Pressure (BP) Excess Cardiovascular Disease  (CVD) Events
Blood pressure: a demonstrated, modifiable risk factor of CVD Elevated Blood Pressure Excess CVD Events Consistent evidence Meaningful effect
How  strong  is the association between higher Na and BP? Elevated Blood Pressure Higher Sodium Intake Data suggest the  magnitude  of the association is  modest
Sodium and BP: a  modest  association ,[object Object],[object Object],[object Object],*Hajjar et al., Arch Intern Med, 2001
Sodium and BP: a modest association ,[object Object],[object Object],1) Ford  & Cooper, Hypertension 1991.  2) Ascherio et al.  Circulation 1992
Sodium and BP: a modest association ,[object Object],[object Object],[object Object],[object Object]
Sodium and BP: a modest association ,[object Object],[object Object],[object Object]
What is the relationship of  sodium intake with CVD events?   A mount    B P sodium  ? B P     C vd   A mount      C vd sodium  Does association of BP with both Na and CVD answer the question?
A correlation exercise: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
To estimate the relationship of  Na with CVD events ,[object Object],Even though Na is associated with BP and BP is associated with CVD… To determine if Na is associated with CVD:
Diet and CVD clinical outcome trials ,[object Object],[object Object],[object Object],Hooper et al. * :  Few studies had clinical outcome data and these had few events.  17 Deaths recorded, evenly divided between intervention and control. *Hooper et al. The Cochrane Database of Systematic Reviews 2004.
Na and CVD: cohort studies MRFIT* Outcome: All-cause mortality  Population: males   Median urinary sodium ~ 117 mmol/d Results: no association *Cutler JA. ASH 1997 (presentation).
Na and CVD: cohort studies Hawaiian Japanese Men*   Outcome: Stroke   Population: men, Japanese ancestry, n=7895   Median dietary sodium: approx. 2000 mg/d Results: no association *Kagan et al. Stroke, 1985.
Na and CVD: cohort studies Worksite Hypertension Program*   Outcome: Myocardial Infarction   Population: Treated hypertensives n=2937   Median urinary sodium (mmol/d):    Men: 126  mmol   Women 97  mmol Results: Inverse association for men   No association for women *Alderman et al. Hypertension, 1995.
Na and CVD: cohort studies Scottish Heart Health Study*   Outcome: All CHD, CHD & All-Cause Mortality   Population: Scottish adults  n= 11,629   Mean urinary sodium mmol/d   males ~ 186 mmol   females ~ 136 mmol Results   Males:  Indirect assoc., All-Cause Mortality  Females: Direct assoc., All CHD   No assoc. for other outcomes, either sex *Tunstall-Pedoe et al., BMJ 1997.
Na and CVD: cohort studies Finland study*   Outcome: CHD; CHD, CVD & All Mortality   Population: Finish adults  n= 2533   Median urinary sodium mmol/d   males = 206 mmol  females = 155 mmol Results:  Direct associations *Tuomilehto et al. Lancet, 2001.
Na and CVD: cohort studies Takayama Study*   Outcome: Stroke Mortality   Population: Japanese adults  n= 39,079   Mean dietary sodium **   males = 5.7 gm  females = 5.2 gm Results:  Direct association with stroke *Nagata et al. Stroke, 2004.  **Mean Na for middle tertile
Na and CVD: cohort studies TOHP  (Trials of hypertension prevention)*   Outcome: All CVD; All cause mortality   Population:  3126 U.S. adults 30-54 y.o. Diastolic 80-89 mmHg;   BMI ≥25 in >90% participants Results for lower Na group:    Significant (p=.044) protection for all CVD   Not significant (p=.35) for all mortality *Cook et al.  BMJ 2007
The NHANES Experience National Health and Nutrition Examination Surveys Representative samples of non-institutionalized adults in the U.S.  Outcome follow-up added after. Sodium and calories from 24-hr dietary recall. Baseline surveys conducted NHANES I    1971-1975 NHANES II    1976-1980 NHANES III  1988-1994
The NHANES Experience NHANES I  (a)  *   Outcome: CVD and All-Cause Mortality   Population: U.S. adults  n= 11,346   Mean dietary sodium: (mg/d)   Men: 2515 mg  Women 1701 mg Results: Inverse association for Na   Direct association for Na/Cal *Alderman et al. Lancet, 1998.
The NHANES Experience NHANES I  (b)   *   Outcome: Stroke, CVD & All-Cause Mortality   Population: U.S. adults  n= 9,485   BMI <27.8  kg/m 2  n=6797  BMI  > 27.8  n=2688 Results:  Direct associations in Overweight  (28%)   No associations in Non-overweight (72%) *He et al. JAMA, 1999.
The NHANES Experience NHANES II*   Outcome:  CVD and All-Cause Mortality   Population:  U.S. adults ages 30-74 at entry  n= 7154 representing 78.9 million Mean dietary sodium:   2718 mg/d    Median:  2360 mg/d  *Cohen et al. Sodium intake and mortality in the NHANES II Follow-up Study.  American Journal of Medicine  (2006) 119: 275.e7-275.e14.
NHANES II * CVD and all-cause mortality *Cohen et al.  AJM,  2006 .  ** rates without weighting;RR with weighting Age-sex adjusted rates**
NHANES II * Adjusted CVD Mortality Hazard Ratios *Cohen et al.  AJM,  2006 . Adjusted for age, sex, race, smoking, alcohol, SBP, BP-txt, BMI, education, physical activity, dietary K, Hx diabetes, cholesterol, (calories) .03 0.80, 0.99 0.89 Na per 1000 mg .04 1.01, 1.49 1.22 Na <residuals adjusted median .03 1.03, 1.81 1.37 Na < 2300 mg .008 0.68, 0.94 0.80 Na mg per calorie P 95% CI H.R. Sodium
NHANES II * All-Cause Mortality Hazard Ratios *Cohen et al.  AJM,  2006 . Adjusted for age, sex, race, smoking, alcohol, SBP, BP-txt, BMI, education, physical activity, dietary K, Hx diabetes, cholesterol, (calories) .06 0.87, 1.00 0.93 Na per 1000 mg .13 0.97, 1.30 1.12 Na <residuals adjusted median .003 1.10, 1.50 1.28 Na < 2300 mg .05 0.79, 1.00 0.89 Na mg per calorie P 95% CI H.R. Na
Adjusted hazard ratios of CVD mortality for Na intake <2300 mg in 27 selected subgroups estimated by Cox models
Adjusted hazard ratios of CVD mortality for Na intake <2300 mg in 27 selected subgroups estimated by Cox models
The NHANES Experience   NHANES III ,[object Object],[object Object],[object Object],[object Object]
NHANES III* Population:  U.S. adults age >30 at entry    Exclusions: CVD at baseline     or on low salt diet for BP   Remaining n = 8699   (representing about 100 million) Mean dietary sodium:   3207  ±   1608  mg/d    Median:  2922 mg/d  (IQR: 2060, 4048) *Cohen et al. Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III), JGIM 2008.
NHANES III* Outcomes:   CVD deaths: 436      (236 CHD,  82 CVA, 118 other)  All-Cause Mortality: 1150 deaths   Mean follow-up time:  8.7 ±2.3 years Hazard ratios  adjusted for age, sex, race/ethnicity,   education, smoking, diabetes, cancer, SBP,   alcohol, physical activity, dietary K, weight,    cholesterol, txt for hypertension and calories  *Cohen et al. Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III), JGIM 2008.
NHANES III * Adjusted CVD Mortality Hazard Ratios *Cohen et al.  JGIM, 2008. Adjusted for age, sex, race/ethnicity, education, smoking, diabetes, cancer, SBP, alcohol, physical activity, dietary K, weight, cholesterol, txt for hypertension (calories for 1 st  row)   .07 0.77, 1.01 0.88 Na per 1000 mg .07 0.77, 1.01 0.88 Na residuals adjusted per 1000 mg .40 0.72, 1.14 0.91 Na mg per calorie P 95% CI H.R. Sodium
NHANES III * Adjusted All-Cause Mortality HRs *Cohen et al.  JGIM, 2008. Adjusted for age, sex, race/ethnicity, education, smoking, diabetes, cancer, SBP, alcohol, physical activity, dietary K, weight, cholesterol, txt for hypertension (calories for 1 st  row)   .11 0.88, 1.01 0.94 Na per 1000 mg .11 0.88, 1.02 0.95 Na residuals adjusted per 1000 mg .94 0.88, 1.12 1.00 Na mg per calorie P 95% CI H.R. Sodium
NHANES III* 99% CI  for Hazard Ratios    per 1000 mg Na CVD mortality:  (.73, 1. 06 ) All cause mortality:  (.86, 1. 04 ) Very small probability of meaningful increased risk of mortality per 1000 mg Na *Cohen et al. Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III). JGIM, 2008.
NHANES Limitations and Strength ,[object Object],[object Object],[object Object],[object Object]
NHANES Strengths  ,[object Object],[object Object],[object Object],[object Object],[object Object]
Potential mechanisms for adverse effects of lower sodium diet  ,[object Object],[object Object],[object Object],[object Object]
Heterogeneity of effects likely ,[object Object],[object Object],[object Object],[object Object],[object Object]
No strong evidence for  either  benefit or harm of sodium restriction With regard to clinical outcomes of morbidity and mortality:
U. S. PREVENTIVE SERVICES TASK FORCE - 2003 ,[object Object],[object Object],U.S. Preventive Services Task Force.  Screening for High Blood Pressure: Recommendations and Rationale . July 2003. Agency for Healthcare Research and Quality, Rockville, MD.  http://www.ahrq.gov/clinic/3rduspstf/highbloodsc/hibloodrr.htm
Should government restrict sodium in processed food? With little and contradictory evidence regarding benefit or harm,  does the rationale of “can’t hurt” apply?
Potential problems from “law of unintended consequences” ,[object Object],[object Object],[object Object],[object Object]
Summary ,[object Object],[object Object]
Acknowledgements ,[object Object],[object Object],[object Object],[object Object]
[object Object]
Contact information: Dr. Hillel W. Cohen Dept. of Epidemiology and Population Health Albert Einstein College of Medicine Bronx, NY 10461, USA 718-430-3745 [email_address]

Más contenido relacionado

La actualidad más candente

The role of exercise in medicine
The role of exercise in medicineThe role of exercise in medicine
The role of exercise in medicine
Nursing Hi Nursing
 
Can treating metabolic acidosis of ckd slow decline in eGFR?
Can treating metabolic acidosis of ckd slow decline in eGFR?Can treating metabolic acidosis of ckd slow decline in eGFR?
Can treating metabolic acidosis of ckd slow decline in eGFR?
Adeel Rafi Ahmed
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
MedicineAndHealthUSA
 

La actualidad más candente (19)

Association of cardio metabolic risk factors, serum nitric oxide metabolite a...
Association of cardio metabolic risk factors, serum nitric oxide metabolite a...Association of cardio metabolic risk factors, serum nitric oxide metabolite a...
Association of cardio metabolic risk factors, serum nitric oxide metabolite a...
 
Plant Based Diets – What's New?
Plant Based Diets – What's New?Plant Based Diets – What's New?
Plant Based Diets – What's New?
 
Bydureon
BydureonBydureon
Bydureon
 
Journal presentation
Journal presentationJournal presentation
Journal presentation
 
The role of exercise in medicine
The role of exercise in medicineThe role of exercise in medicine
The role of exercise in medicine
 
Diabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coinDiabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coin
 
B042106011
B042106011B042106011
B042106011
 
Hypertension with comorbidity
Hypertension with comorbidityHypertension with comorbidity
Hypertension with comorbidity
 
Cvd risk in dm
Cvd risk in dmCvd risk in dm
Cvd risk in dm
 
Can treating metabolic acidosis of ckd slow decline in eGFR?
Can treating metabolic acidosis of ckd slow decline in eGFR?Can treating metabolic acidosis of ckd slow decline in eGFR?
Can treating metabolic acidosis of ckd slow decline in eGFR?
 
Dm medications cv safety
Dm medications cv safetyDm medications cv safety
Dm medications cv safety
 
Bariatric Surgery and Kidney Stones
Bariatric Surgery and Kidney StonesBariatric Surgery and Kidney Stones
Bariatric Surgery and Kidney Stones
 
Advances in type 2 dm therapy
Advances in type 2 dm therapyAdvances in type 2 dm therapy
Advances in type 2 dm therapy
 
ckd
ckdckd
ckd
 
ASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney Disease
 
Abcc1
Abcc1Abcc1
Abcc1
 
Calcium and Hypertension
 Calcium and Hypertension  Calcium and Hypertension
Calcium and Hypertension
 
New Approaches To The Treatment Of Hyperphosphataemia (CRF)
New Approaches To The Treatment Of Hyperphosphataemia (CRF)New Approaches To The Treatment Of Hyperphosphataemia (CRF)
New Approaches To The Treatment Of Hyperphosphataemia (CRF)
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
 

Similar a Salt and Cardiovascular Mortality

Contraversies in hypertension management
Contraversies in hypertension managementContraversies in hypertension management
Contraversies in hypertension management
Shyam Jadhav
 
Blood pressure control in diabetes
Blood pressure control in diabetesBlood pressure control in diabetes
Blood pressure control in diabetes
BALASUBRAMANIAM IYER
 
T h e n e w e n g l a n d j o u r n a l o f m e d i c i n.docx
T h e  n e w  e n g l a n d  j o u r n a l  o f  m e d i c i n.docxT h e  n e w  e n g l a n d  j o u r n a l  o f  m e d i c i n.docx
T h e n e w e n g l a n d j o u r n a l o f m e d i c i n.docx
ssuserf9c51d
 
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
MedicineAndFamily
 
An Evidence Based Approach To Hypertension
An Evidence Based Approach To HypertensionAn Evidence Based Approach To Hypertension
An Evidence Based Approach To Hypertension
Aline Chammas
 

Similar a Salt and Cardiovascular Mortality (20)

Trials of diet and lifestyle modifications: Food fights and other battles
Trials of diet and lifestyle modifications: Food fights and other battlesTrials of diet and lifestyle modifications: Food fights and other battles
Trials of diet and lifestyle modifications: Food fights and other battles
 
Htn combination thrapy f
Htn combination thrapy fHtn combination thrapy f
Htn combination thrapy f
 
Contraversies in hypertension management
Contraversies in hypertension managementContraversies in hypertension management
Contraversies in hypertension management
 
Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014
 
The Health Effects of Reducing Sodium and Improving Overall Diet
The Health Effects of Reducing Sodium and Improving Overall DietThe Health Effects of Reducing Sodium and Improving Overall Diet
The Health Effects of Reducing Sodium and Improving Overall Diet
 
Blood pressure control in diabetes
Blood pressure control in diabetesBlood pressure control in diabetes
Blood pressure control in diabetes
 
Obesity paradox
Obesity paradoxObesity paradox
Obesity paradox
 
Current trends in cardiovascular assessment
Current trends in cardiovascular assessmentCurrent trends in cardiovascular assessment
Current trends in cardiovascular assessment
 
Journal club: Urinary sodium excretion and cardiovascular risk
Journal club: Urinary sodium excretion and cardiovascular riskJournal club: Urinary sodium excretion and cardiovascular risk
Journal club: Urinary sodium excretion and cardiovascular risk
 
Hta diureticos punto fijo
Hta diureticos punto  fijoHta diureticos punto  fijo
Hta diureticos punto fijo
 
Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?
 
T h e n e w e n g l a n d j o u r n a l o f m e d i c i n.docx
T h e  n e w  e n g l a n d  j o u r n a l  o f  m e d i c i n.docxT h e  n e w  e n g l a n d  j o u r n a l  o f  m e d i c i n.docx
T h e n e w e n g l a n d j o u r n a l o f m e d i c i n.docx
 
66 hypertension
66 hypertension66 hypertension
66 hypertension
 
Managing Type 2 Diabetes
Managing Type 2 DiabetesManaging Type 2 Diabetes
Managing Type 2 Diabetes
 
Treatment of Hypertension A Review.pdf
Treatment of Hypertension A Review.pdfTreatment of Hypertension A Review.pdf
Treatment of Hypertension A Review.pdf
 
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
 
Update in hypertension management
Update in hypertension managementUpdate in hypertension management
Update in hypertension management
 
DM Lessons and Guidance
DM Lessons and GuidanceDM Lessons and Guidance
DM Lessons and Guidance
 
An Evidence Based Approach To Hypertension
An Evidence Based Approach To HypertensionAn Evidence Based Approach To Hypertension
An Evidence Based Approach To Hypertension
 
Diabetic Nephropathy 2009
Diabetic Nephropathy 2009Diabetic Nephropathy 2009
Diabetic Nephropathy 2009
 

Último

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
DR SETH JOTHAM
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
MedicoseAcademics
 

Último (20)

BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediatesBMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
CNN-based plastic waste detection system
CNN-based plastic waste detection systemCNN-based plastic waste detection system
CNN-based plastic waste detection system
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
MRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptxMRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptx
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial health
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communications
 
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. MacklinScleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
 
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdfรายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feel
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 

Salt and Cardiovascular Mortality

  • 1. Sodium intake and mortality Perspectives on the evidence from the U.S. National Health and Nutrition Examination Surveys (NHANES) Hillel W. Cohen, MPH, DrPH Associate Professor of Epidemiology and Population Health Albert Einstein College of Medicine, Bronx NY
  • 2. The Sodium Hypothesis Higher Sodium (Na) Intake Elevated Blood Pressure (BP) Excess Cardiovascular Disease (CVD) Events
  • 3. Blood pressure: a demonstrated, modifiable risk factor of CVD Elevated Blood Pressure Excess CVD Events Consistent evidence Meaningful effect
  • 4. How strong is the association between higher Na and BP? Elevated Blood Pressure Higher Sodium Intake Data suggest the magnitude of the association is modest
  • 5.
  • 6.
  • 7.
  • 8.
  • 9. What is the relationship of sodium intake with CVD events? A mount B P sodium ? B P C vd A mount C vd sodium Does association of BP with both Na and CVD answer the question?
  • 10.
  • 11.
  • 12.
  • 13. Na and CVD: cohort studies MRFIT* Outcome: All-cause mortality Population: males Median urinary sodium ~ 117 mmol/d Results: no association *Cutler JA. ASH 1997 (presentation).
  • 14. Na and CVD: cohort studies Hawaiian Japanese Men* Outcome: Stroke Population: men, Japanese ancestry, n=7895 Median dietary sodium: approx. 2000 mg/d Results: no association *Kagan et al. Stroke, 1985.
  • 15. Na and CVD: cohort studies Worksite Hypertension Program* Outcome: Myocardial Infarction Population: Treated hypertensives n=2937 Median urinary sodium (mmol/d): Men: 126 mmol Women 97 mmol Results: Inverse association for men No association for women *Alderman et al. Hypertension, 1995.
  • 16. Na and CVD: cohort studies Scottish Heart Health Study* Outcome: All CHD, CHD & All-Cause Mortality Population: Scottish adults n= 11,629 Mean urinary sodium mmol/d males ~ 186 mmol females ~ 136 mmol Results Males: Indirect assoc., All-Cause Mortality Females: Direct assoc., All CHD No assoc. for other outcomes, either sex *Tunstall-Pedoe et al., BMJ 1997.
  • 17. Na and CVD: cohort studies Finland study* Outcome: CHD; CHD, CVD & All Mortality Population: Finish adults n= 2533 Median urinary sodium mmol/d males = 206 mmol females = 155 mmol Results: Direct associations *Tuomilehto et al. Lancet, 2001.
  • 18. Na and CVD: cohort studies Takayama Study* Outcome: Stroke Mortality Population: Japanese adults n= 39,079 Mean dietary sodium ** males = 5.7 gm females = 5.2 gm Results: Direct association with stroke *Nagata et al. Stroke, 2004. **Mean Na for middle tertile
  • 19. Na and CVD: cohort studies TOHP (Trials of hypertension prevention)* Outcome: All CVD; All cause mortality Population: 3126 U.S. adults 30-54 y.o. Diastolic 80-89 mmHg; BMI ≥25 in >90% participants Results for lower Na group: Significant (p=.044) protection for all CVD Not significant (p=.35) for all mortality *Cook et al. BMJ 2007
  • 20. The NHANES Experience National Health and Nutrition Examination Surveys Representative samples of non-institutionalized adults in the U.S. Outcome follow-up added after. Sodium and calories from 24-hr dietary recall. Baseline surveys conducted NHANES I 1971-1975 NHANES II 1976-1980 NHANES III 1988-1994
  • 21. The NHANES Experience NHANES I (a) * Outcome: CVD and All-Cause Mortality Population: U.S. adults n= 11,346 Mean dietary sodium: (mg/d) Men: 2515 mg Women 1701 mg Results: Inverse association for Na Direct association for Na/Cal *Alderman et al. Lancet, 1998.
  • 22. The NHANES Experience NHANES I (b) * Outcome: Stroke, CVD & All-Cause Mortality Population: U.S. adults n= 9,485 BMI <27.8 kg/m 2 n=6797 BMI > 27.8 n=2688 Results: Direct associations in Overweight (28%) No associations in Non-overweight (72%) *He et al. JAMA, 1999.
  • 23. The NHANES Experience NHANES II* Outcome: CVD and All-Cause Mortality Population: U.S. adults ages 30-74 at entry n= 7154 representing 78.9 million Mean dietary sodium: 2718 mg/d Median: 2360 mg/d *Cohen et al. Sodium intake and mortality in the NHANES II Follow-up Study. American Journal of Medicine (2006) 119: 275.e7-275.e14.
  • 24. NHANES II * CVD and all-cause mortality *Cohen et al. AJM, 2006 . ** rates without weighting;RR with weighting Age-sex adjusted rates**
  • 25. NHANES II * Adjusted CVD Mortality Hazard Ratios *Cohen et al. AJM, 2006 . Adjusted for age, sex, race, smoking, alcohol, SBP, BP-txt, BMI, education, physical activity, dietary K, Hx diabetes, cholesterol, (calories) .03 0.80, 0.99 0.89 Na per 1000 mg .04 1.01, 1.49 1.22 Na <residuals adjusted median .03 1.03, 1.81 1.37 Na < 2300 mg .008 0.68, 0.94 0.80 Na mg per calorie P 95% CI H.R. Sodium
  • 26. NHANES II * All-Cause Mortality Hazard Ratios *Cohen et al. AJM, 2006 . Adjusted for age, sex, race, smoking, alcohol, SBP, BP-txt, BMI, education, physical activity, dietary K, Hx diabetes, cholesterol, (calories) .06 0.87, 1.00 0.93 Na per 1000 mg .13 0.97, 1.30 1.12 Na <residuals adjusted median .003 1.10, 1.50 1.28 Na < 2300 mg .05 0.79, 1.00 0.89 Na mg per calorie P 95% CI H.R. Na
  • 27. Adjusted hazard ratios of CVD mortality for Na intake <2300 mg in 27 selected subgroups estimated by Cox models
  • 28. Adjusted hazard ratios of CVD mortality for Na intake <2300 mg in 27 selected subgroups estimated by Cox models
  • 29.
  • 30. NHANES III* Population: U.S. adults age >30 at entry Exclusions: CVD at baseline or on low salt diet for BP Remaining n = 8699 (representing about 100 million) Mean dietary sodium: 3207 ± 1608 mg/d Median: 2922 mg/d (IQR: 2060, 4048) *Cohen et al. Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III), JGIM 2008.
  • 31. NHANES III* Outcomes: CVD deaths: 436 (236 CHD, 82 CVA, 118 other) All-Cause Mortality: 1150 deaths Mean follow-up time: 8.7 ±2.3 years Hazard ratios adjusted for age, sex, race/ethnicity, education, smoking, diabetes, cancer, SBP, alcohol, physical activity, dietary K, weight, cholesterol, txt for hypertension and calories *Cohen et al. Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III), JGIM 2008.
  • 32. NHANES III * Adjusted CVD Mortality Hazard Ratios *Cohen et al. JGIM, 2008. Adjusted for age, sex, race/ethnicity, education, smoking, diabetes, cancer, SBP, alcohol, physical activity, dietary K, weight, cholesterol, txt for hypertension (calories for 1 st row) .07 0.77, 1.01 0.88 Na per 1000 mg .07 0.77, 1.01 0.88 Na residuals adjusted per 1000 mg .40 0.72, 1.14 0.91 Na mg per calorie P 95% CI H.R. Sodium
  • 33. NHANES III * Adjusted All-Cause Mortality HRs *Cohen et al. JGIM, 2008. Adjusted for age, sex, race/ethnicity, education, smoking, diabetes, cancer, SBP, alcohol, physical activity, dietary K, weight, cholesterol, txt for hypertension (calories for 1 st row) .11 0.88, 1.01 0.94 Na per 1000 mg .11 0.88, 1.02 0.95 Na residuals adjusted per 1000 mg .94 0.88, 1.12 1.00 Na mg per calorie P 95% CI H.R. Sodium
  • 34. NHANES III* 99% CI for Hazard Ratios per 1000 mg Na CVD mortality: (.73, 1. 06 ) All cause mortality: (.86, 1. 04 ) Very small probability of meaningful increased risk of mortality per 1000 mg Na *Cohen et al. Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III). JGIM, 2008.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39. No strong evidence for either benefit or harm of sodium restriction With regard to clinical outcomes of morbidity and mortality:
  • 40.
  • 41. Should government restrict sodium in processed food? With little and contradictory evidence regarding benefit or harm, does the rationale of “can’t hurt” apply?
  • 42.
  • 43.
  • 44.
  • 45.
  • 46. Contact information: Dr. Hillel W. Cohen Dept. of Epidemiology and Population Health Albert Einstein College of Medicine Bronx, NY 10461, USA 718-430-3745 [email_address]